# EDGAR Filing Document

**Accession Number:** 0001581178
**File Stem:** 0000899140-25-001321
**Filing Date:** 2025-11
**Character Count:** 7487
**Document Hash:** c7c4c5caa36e4245f4d4851177171a14
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899140-25-001321.hdr.sgml**: 20251114

**ACCESSION NUMBER**: 0000899140-25-001321

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251114

**DATE AS OF CHANGE**: 20251114

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EUPRAXIA PHARMACEUTICALS INC.
- **CENTRAL INDEX KEY:** 0001581178
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94690
- **FILM NUMBER:** 251487375

**BUSINESS ADDRESS:**
- **STREET 1:** 201-2067 CADBORO BAY RD.
- **CITY:** VICTORIA
- **STATE:** A1
- **ZIP:** V8R 5G4
- **BUSINESS PHONE:** 250-590-3968

**MAIL ADDRESS:**
- **STREET 1:** 201-2067 CADBORO BAY RD.
- **CITY:** VICTORIA
- **STATE:** A1
- **ZIP:** V8R 5G4
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DISBROW ROBERT
- **CENTRAL INDEX KEY:** 0001515937

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**MAIL ADDRESS:**
- **STREET 1:** #700-200 BURRARD ST
- **CITY:** VANCUOVER
- **STATE:** A1
- **ZIP:** V6C 3L6

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Issuer:** Eupraxia Pharmaceuticals Inc.

**Title of Class of Securities:** Common Shares, with no par value

**CUSIP Number:** 29842P105

**Date of Event Which Requires Filing of this Statement:** 09/30/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [ ] Rule 13d-1(c)

- [x] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Robert Disbrow | Names of Reporting Persons<br>Robert Disbrow |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>Z4 | Citizenship or Place of Organization<br>Z4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>3568150 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>3568150 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3568150 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3568150 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>7% | Percent of Class Represented by Amount in Row (9)<br>7% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** (1) Rows 7, 9 and 11 includes (a) 3,068,150 shares of the Issuer's (as defined below) common shares, with no par value (the "Common Shares") and 200,000 Common Shares underlying Issuer's Series 1 preferred shares, with no par value (the "Preferred Shares") jointly owned by Robert Disbrow and Kim Kawaguchi, husband and wife (the "Disbrows"); and (b) 300,000 Common Shares held by the children of the Disbrows. The Disbrows disclaim beneficial ownership of the Common Shares held by their children. 
(2) Row 13 is calculated based on the Common Shares and Preferred Shares, beneficially owned by the Reporting Person relative to the Issuer's 50,598,331 outstanding Common Shares, as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 4, 2025, plus the 200,000 Preferred Shares.

---

**Item 1(a). Name of Issuer:**
Eupraxia Pharmaceuticals Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada, V8R 5GR

**Item 2(a). Name of Person Filing:**
This Schedule 13G is being filed by Robert Disbrow (the "Reporting Person").

**Item 2(b). Address of Principal Business Office:**
200 Burrard Street, Suite 700, Vancouver, BC V6C 3L6

**Item 2(c). Citizenship:**
Canada

**Item 2(d). Title of Class of Securities:**
Common Shares, with no par value

**Item 2(e). CUSIP Number:**
29842P105

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

3,568,150

**(b) Percent of class:**

7.0

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

0

**(ii) Shared power to vote or to direct the vote:**

3,568,150

**(iii) Sole power to dispose or to direct the disposition of:**

0

**(iv) Shared power to dispose or to direct the disposition of:**

3,568,150

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

—

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Robert Disbrow**

**Date:** 11/14/2025

**By:** /s/ Robert Disbrow

**Name & Title:** Robert Disbrow